JP2024505274A5 - - Google Patents
Info
- Publication number
- JP2024505274A5 JP2024505274A5 JP2023547031A JP2023547031A JP2024505274A5 JP 2024505274 A5 JP2024505274 A5 JP 2024505274A5 JP 2023547031 A JP2023547031 A JP 2023547031A JP 2023547031 A JP2023547031 A JP 2023547031A JP 2024505274 A5 JP2024505274 A5 JP 2024505274A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- rmva
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144834P | 2021-02-02 | 2021-02-02 | |
| US63/144,834 | 2021-02-02 | ||
| PCT/US2022/014970 WO2022169895A1 (en) | 2021-02-02 | 2022-02-02 | Viral constructs for use in enhancing t-cell priming during vaccination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505274A JP2024505274A (ja) | 2024-02-05 |
| JP2024505274A5 true JP2024505274A5 (cg-RX-API-DMAC7.html) | 2025-02-06 |
Family
ID=82741782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547031A Pending JP2024505274A (ja) | 2021-02-02 | 2022-02-02 | ワクチン接種中のt細胞プライミングの強化において使用されるウイルスコンストラクト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240344082A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4288076A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024505274A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240001116A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117177763A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022215566A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023015467A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206004A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL304805A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023009008A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202246514A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022169895A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111533785B (zh) * | 2020-02-11 | 2022-03-08 | 北京市肿瘤防治研究所 | 靶向免疫检查点tim3结合肽及其应用 |
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| WO2024206243A1 (en) * | 2023-03-24 | 2024-10-03 | Geovax. Inc. | Pan-betacoronavirus vaccines and uses thereof |
| WO2025072383A1 (en) * | 2023-09-25 | 2025-04-03 | The Broad Institute, Inc. | Viral open reading frames, uses thereof, and methods of detecting the same |
| CN117904069B (zh) * | 2024-01-04 | 2025-07-15 | 华中农业大学 | VirEN蛋白介导的DNA拼接和基因编辑方法 |
| GB202409284D0 (en) * | 2024-06-27 | 2024-08-14 | Univ Oxford Innovation Ltd | Mrna platform |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| UA82479C2 (uk) | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| DK2402451T3 (en) | 2006-08-25 | 2018-06-25 | The Government Of The Us Secretary Department Of Health And Human Services | Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector |
| US20100305002A1 (en) | 2009-04-27 | 2010-12-02 | Roswell Park Cancer Institute | Reagents and Methods for Producing Bioactive Secreted Peptides |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| US9884075B2 (en) * | 2014-01-16 | 2018-02-06 | California Institute Of Technology | Domain-swap T cell receptors |
| DK3552615T3 (da) * | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| EP4122492A1 (en) * | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| DK3512536T3 (da) | 2016-09-15 | 2020-11-23 | Leidos Inc | Pd-1-peptidinhibitorer |
| IL319942A (en) | 2016-11-02 | 2025-05-01 | Evans David | Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof |
| EP3630807B1 (en) | 2017-05-25 | 2025-08-13 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| US20210155955A1 (en) * | 2018-04-11 | 2021-05-27 | Cancer Targeting Systems, Inc. | Therapeutic constructs for treating cancer |
| CA3099330A1 (en) | 2018-05-02 | 2019-11-07 | Tonix Pharma Holdings Limited | Synthetic chimeric vaccinia virus |
| US12559526B2 (en) * | 2018-10-15 | 2026-02-24 | The Regents Of The University Of California | Complement component 1s (C1s) deficient cells for production of vaccines and biopharmaceutical proteins |
| CN115397998A (zh) | 2020-02-03 | 2022-11-25 | 希望之城 | 由天然或合成dna产生的基于痘病毒的载体及其用途 |
-
2022
- 2022-02-02 BR BR112023015467A patent/BR112023015467A2/pt unknown
- 2022-02-02 AU AU2022215566A patent/AU2022215566A1/en active Pending
- 2022-02-02 CN CN202280021291.5A patent/CN117177763A/zh active Pending
- 2022-02-02 WO PCT/US2022/014970 patent/WO2022169895A1/en not_active Ceased
- 2022-02-02 EP EP22750341.4A patent/EP4288076A4/en active Pending
- 2022-02-02 KR KR1020237029493A patent/KR20240001116A/ko active Pending
- 2022-02-02 JP JP2023547031A patent/JP2024505274A/ja active Pending
- 2022-02-02 CA CA3206004A patent/CA3206004A1/en active Pending
- 2022-02-02 MX MX2023009008A patent/MX2023009008A/es unknown
- 2022-02-07 TW TW111104426A patent/TW202246514A/zh unknown
-
2023
- 2023-07-27 IL IL304805A patent/IL304805A/en unknown
- 2023-08-01 US US18/229,070 patent/US20240344082A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022160401A5 (cg-RX-API-DMAC7.html) | ||
| JP2025166834A5 (cg-RX-API-DMAC7.html) | ||
| Ferko et al. | Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice | |
| JP2025184979A5 (cg-RX-API-DMAC7.html) | ||
| Nagai | Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding | |
| JP2003510050A5 (cg-RX-API-DMAC7.html) | ||
| Ohgimoto et al. | Sequence analysis of P gene of human parainfluenza type 2 virus: P and cysteine-rich proteins are translated by two mRNAs that differ by two nontemplated G residues | |
| EP3805392A2 (en) | Nucleic acid sequence expressing sars-cov-2 virus antigen peptide and use thereof | |
| AU2004245859B2 (en) | Cell surface expression vector of SARS virus antigen and microorganisms transformed thereby | |
| JP2007513634A5 (cg-RX-API-DMAC7.html) | ||
| JP2022502077A5 (cg-RX-API-DMAC7.html) | ||
| JP2020536489A5 (cg-RX-API-DMAC7.html) | ||
| JP2018515096A5 (cg-RX-API-DMAC7.html) | ||
| JP2007537761A (ja) | Tc−83由来アルファウイルスベクター、粒子および方法 | |
| JP2007502101A5 (cg-RX-API-DMAC7.html) | ||
| JPH09322781A5 (cg-RX-API-DMAC7.html) | ||
| JP2002510494A5 (cg-RX-API-DMAC7.html) | ||
| JP2002542827A5 (cg-RX-API-DMAC7.html) | ||
| RU2733831C1 (ru) | Искусственный ген, кодирующий бицистронную структуру, образованную последовательностями рецептор-связующего домена гликопротеина S коронавируса SARS-CoV-2, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_SC2, обеспечивающая экспрессию искусственного гена и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_SC2, используемого для создания вакцины против коронавируса SARS-CoV-2 | |
| JP2022513326A5 (cg-RX-API-DMAC7.html) | ||
| JP2025503468A5 (cg-RX-API-DMAC7.html) | ||
| JP2020534284A5 (cg-RX-API-DMAC7.html) | ||
| JP2023542297A5 (cg-RX-API-DMAC7.html) | ||
| JP2023522708A5 (cg-RX-API-DMAC7.html) | ||
| WO2021207848A1 (en) | Mers-cov vaccine |